» » Clinical Manual of Child and Adolescent Psychopharmacology

Download Clinical Manual of Child and Adolescent Psychopharmacology fb2

by Robert L. Findling
Download Clinical Manual of Child and Adolescent Psychopharmacology fb2
Medicine
  • Author:
    Robert L. Findling
  • ISBN:
    1585622508
  • ISBN13:
    978-1585622504
  • Genre:
  • Publisher:
    American Psychiatric Publishing, Inc.; 1 edition (October 15, 2007)
  • Pages:
    572 pages
  • Subcategory:
    Medicine
  • Language:
  • FB2 format
    1514 kb
  • ePUB format
    1517 kb
  • DJVU format
    1588 kb
  • Rating:
    4.1
  • Votes:
    659
  • Formats:
    mbr doc lit lrf


From the Inside Flap My go-to reference book for children & adolescent behavioral health.

From the Inside Flap. The Clinical Manual of Child and Adolescent Psychopharmacology is designed to help clinicians provide the best evidence-based and most up-to-date care for the pediatric patient population. My go-to reference book for children & adolescent behavioral health. I'm a PMHNP in my first year of practice and have yet to ask a question on this subject that this book doesn't have the answer to. I refer to it several times a week. 3 people found this helpful.

Green's Child and Adolescent Clinical Psychopharmacology. Dr. Findling has assembled an outstanding group of to contribute to this manual of pediatric psychopharmacology.

Start by marking Clinical Manual of Child and Adolescent Psychopharmacology as Want to Read .

Start by marking Clinical Manual of Child and Adolescent Psychopharmacology as Want to Read: Want to Read savin. ant to Read.

Request PDF On Sep 15, 2009, Vishal Madaan and others published Clinical Manual of Child and Adolescent Psychopharmacology .

The rate of diagnosis and treatment is increasing in adolescents despite considerable controversy regard-ing criteria for diagnosis. Ziprasidone is an atypical neuroleptic with novel receptor-binding activity and a favorable side effect profile.

Robert L. Findling, . is Director of the Division of Child and Adolescent Psychiatry and Vice Chair of the Department of Psychiatry and Behavioral Sciences at Johns Hopkins Hospital in Baltimore, Maryland. This book should be on the shelf of every fellow and practitioner in child and adolescent psychiatry, pediatrician, family physician, psychiatric advanced practice nurse, and general psychiatrist who treats children and adolescents.

DSM-5 criteria and information on comorbidities are also included.

Molly McVoy, Robert L Findling. To this end, the book describes and explores those elements that are specific to pediatric psychopharmacology; this defines and positions the volume at the nexus of child and adolescent psychiatry, pediatrics, and pharmacology.

Download books for free. Clinical Manual of Child and Adolescent Psychopharmacology.

By Robert L. Findling.

Part II. Clinical Psychopharmacology. Yet sometimes we have to return to the basics. By Robert L. In 1990, when I was a child and adolescent psychiatry fellow, the entire field of pediatric psychopharmacology was contained in a book chapter. Now, less than 20 years later, enough work has been done to fill an entire book.

Clinical Manual of Child and Adolescent Psychopharmacology is a succinct and practical guide that enables practitioners to more effectively address commonly-seen disorders such as ADHD, gain new insight into high-profile problems like juvenile suicide, and become better informed regarding conditions, such as anxiety, that frequently go undiagnosed and untreated. The contributors review developmental aspects of pediatric psychopharmacology, address specific disorders in chapter-length detail, and discuss the pharmacotherapy of youths who are primarily seen in general medical settings, covering such conditions as functional somatic syndromes and somatoform disorders, eating disorders, sleep disorders, elimination disorders, and delirium. Specific chapters cover the problems that practitioners find most vexing, including the use of stimulant and nonstimulant agents for attention-deficit/hyperactivity disorder, pharmacological approaches to patients with disruptive behavior disorders, benefits and risks of medications for anxiety disorders, combination pharmacotherapeutic approaches for bipolar disorders, and use of antidepressants for autism and other pervasive developmental disorders. Throughout the text, the contributors provide commentary regarding the clinical interpretability of existing literature to better enable clinicians to incorporate re into their practice.

Yggfyn
This is an excellent text for the clinician who treats children and adolescents with psychotropic medications. There are 10 chapters, each written by a group of experts in each area, with clear dosing and side effect information. This text is a great reference for child psychiatrists, adult psychiatrists, developmental pediatricians and advanced practice nurses. There are no other texts that are as concise and current as this one.
wanderpool
I am sending this book back and asking for a refund.I am a 65 yo MD practicing CHild,adolescent and adult Psychiatry for 34 years in California.The majority of my work is outpatient but this book has two glaring deficiencies that make it suspect.
No 1. In the section on Bipolar disorder, the authors enthusiastically endorse and encourage the use of Carbamazepin (Tegretol) as a first line drug for teens.Blood work every week for the first few.Hello, have they not heard of Oxycarbamazepine (Trileptal) which is Tegretal with a few different molecules.THere are NO side effects of real merit with Trileptal, no liver enzyime elevations and no blood work.I,ve used it with lots of teens and some under ten for the past 4 years that I learned about it, from Dr. T> WILENS at Harvard Medical school.
Secondly, the antidepressant Cymbalta is NOT EVEN MENTIONED inthe book tho its been availble for three years and works well in teens,even if not approved by the fda.. Thirdly, the section on tic disorders is not even written by a Physician.
Also there is little discussion on the very controversial finding by the fda, that black box warning about increased suicidal ideation be placed on several ssri,s.I called 9 of my colleagues, with a total clinical experience profile of about 288 years and NOT ONE has ever seen increased suicidal ideation soon after the start of any of the SSRI,s and the newer antidepressants.
ALso the section on Bipolar illness is short,superficial and doesn,t do real justice to the gravity of the illness in small children and the difficulty in diagnosis.
This book is not worth fifty bucks.
Shomeshet
In contrast to the review above, I would recommend buying this book, albeit form a very different perspective as a graduating child psychiatry fellow. The discussion of the controversy around SSRI's and suicidality is substantial yet concise - it clarifies the terms of the debate by accurately reporting the evidence without editorializing. I found it helpful. This specific issue is representative of the overall strength of the book - it provides a succinct summary of the evidence supporting (or not supporting) medications used in most (but not all) of the major illnesses seen in child psychiatry. It also provides helpful data and tables on guidelines and dosing schedules. No, the book is not exhaustive, but I have found it extraordinarily useful - particularly because it deals squarely with what we know and what we don't know about the medications and treatments we have available to us. When talking with families and patients, I have found that informed and collaboratve treatment decisions have to start with an honest discussion of risks and benefits and this book has been a key piece of this process, in addition to serving as a guide for the nuts and bolts of management once treatment has started. I highly recommend it.